The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

MOPEG     1-(4-hydroxy-3-methoxy- phenyl)ethane-1,2-diol

Synonyms: Vanylglycol, HMPG, MHPG, SureCN43536, HMDB01490, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.



Psychiatry related information on METHOXYHYDROXYPHENYLGLYCOL




Chemical compound and disease context of METHOXYHYDROXYPHENYLGLYCOL



  • Long-term alprazolam treatment significantly reduced plasma MHPG baseline and blunted the yohimbine-induced increases in plasma MHPG, anxiety-nervousness, and sitting systolic blood pressure [17].
  • The MHPG concentrations in CSF also showed significant positive correlations with heart rate, systolic and diastolic blood pressures, tremor, anorexia, and sweating [18].
  • The physiological changes in levels of MHPG excretion associated with the circadian rhythm were at least as great as pathological changes associated with manic-depressive illness [19].
  • CONCLUSIONS: Short-term anabolic androgenic steroid use affects brain neurochemistry, increasing CSF 5-HIAA and decreasing MHPG [20].
  • There was a detectable but nonsignificant genotype effect on 5-HIAA and no effects on MHPG [21].



Associations of METHOXYHYDROXYPHENYLGLYCOL with other chemical compounds




Analytical, diagnostic and therapeutic context of METHOXYHYDROXYPHENYLGLYCOL


  1. The clinical syndrome of striatal dopamine deficiency. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Burns, R.S., LeWitt, P.A., Ebert, M.H., Pakkenberg, H., Kopin, I.J. N. Engl. J. Med. (1985) [Pubmed]
  2. 3-Methoxy-4-hydroxyphenylglycol in cerebrospinal fluid and vanillylmandelic acid in urine of humans with hypertension. Saran, R.K., Sahuja, R.C., Gupta, N.N., Hasan, M., Bhargava, K.P., Shanker, K., Kishor, K. Science (1978) [Pubmed]
  3. Urinary MHPG excretion in minimal brain dysfunction and its modification by d-amphetamine. Shekim, W.O., Dekirmenjian, H., Chapel, J.L. The American journal of psychiatry. (1979) [Pubmed]
  4. Raised plasma concentrations of 3-methoxy-4-hydroxyphenylethyleneglycol in cirrhotic patients with or without hepatic encephalopathy. Echizen, H., Minegishi, A., Hayashi, S., Umeda, N., Oda, T., Ishizaki, T. Gut (1989) [Pubmed]
  5. Growth hormone catecholamines in affective disease. Garver, D.L., Pandey, G.N., Dekirmenjian, H., Deleon-Jones, F. The American journal of psychiatry. (1975) [Pubmed]
  6. Afternoon continuous plasma levels of 3-methoxy-4-hydroxyphenylglycol and age. Distinctive biologic subgroups of endogenous depression? Halbreich, U., Sharpless, N., Asnis, G.M., Endicott, J., Goldstein, S., Vital-Herne, J., Eisenberg, J., Zander, K., Kang, B.J., Shindledecker, R. Arch. Gen. Psychiatry (1987) [Pubmed]
  7. Situational panic attacks. Behavioral, physiologic, and biochemical characterization. Woods, S.W., Charney, D.S., McPherson, C.A., Gradman, A.H., Heninger, G.R. Arch. Gen. Psychiatry (1987) [Pubmed]
  8. Urinary 3-methoxy-4-hydroxyphenylglycol and major affective disorders. A replication and new findings. Muscettola, G., Potter, W.Z., Pickar, D., Goodwin, F.K. Arch. Gen. Psychiatry (1984) [Pubmed]
  9. State anxiety, physical activity, and urinary 3-methoxy-4-hydroxyphenethylene glycol excretion. Sweeney, D.R., Maas, J.W., Heninger, G.R. Arch. Gen. Psychiatry (1978) [Pubmed]
  10. Blunted growth hormone response to clonidine in patients with generalized anxiety disorder. Abelson, J.L., Glitz, D., Cameron, O.G., Lee, M.A., Bronzo, M., Curtis, G.C. Arch. Gen. Psychiatry (1991) [Pubmed]
  11. Relation between plasma and cerebrospinal fluid levels of 3-methoxy-4-hydroxyphenylglycol. Kopin, I.J., Gordon, E.K., Jimerson, D.C., Polinsky, R.J. Science (1983) [Pubmed]
  12. Specific and sensitive radioimmunoassay for 3-methoxy-4-hydroxyphenylethyleneglycol (MOPEG). Keeton, T.K., Krutzsch, H., Lovenberg, W. Science (1981) [Pubmed]
  13. Decreased stress responsivity of central and peripheral catecholaminergic systems in aged 344/N Fischer rats. Cizza, G., Pacak, K., Kvetnansky, R., Palkovits, M., Goldstein, D.S., Brady, L.S., Fukuhara, K., Bergamini, E., Kopin, I.J., Blackman, M.R. J. Clin. Invest. (1995) [Pubmed]
  14. Extraversion in pathological gamblers. Correlates with indexes of noradrenergic function. Roy, A., De Jong, J., Linnoila, M. Arch. Gen. Psychiatry (1989) [Pubmed]
  15. Cerebrospinal fluid neurochemistry in children and adolescents with obsessive-compulsive disorder. Swedo, S.E., Leonard, H.L., Kruesi, M.J., Rettew, D.C., Listwak, S.J., Berrettini, W., Stipetic, M., Hamburger, S., Gold, P.W., Potter, W.Z. Arch. Gen. Psychiatry (1992) [Pubmed]
  16. Toward a biochemical classification of depressive disorders, VII: urinary free cortisol and urinary MHPG in depressions. Rosenbaum, A.H., Maruta, T., Schatzberg, A.F., Orsulak, P.J., Jiang, N.S., Cole, J.O., Schildkraut, J.J. The American journal of psychiatry. (1983) [Pubmed]
  17. Noradrenergic function and the mechanism of action of antianxiety treatment. I. The effect of long-term alprazolam treatment. Charney, D.S., Heninger, G.R. Arch. Gen. Psychiatry (1985) [Pubmed]
  18. Cerebrospinal fluid 3-methoxy-4-hydroxyphenylglycol and norepinephrine levels in alcohol withdrawal. Correlations with clinical signs. Hawley, R.J., Major, L.F., Schulman, E.A., Linnoila, M. Arch. Gen. Psychiatry (1985) [Pubmed]
  19. Urinary 3-methoxy-4-hydroxyphenylglycol circadian rhythm. Early timing (phase-advance) in manic-depressives compared with normal subjects. Wehr, T.A., Muscettola, G., Goodwin, F.K. Arch. Gen. Psychiatry (1980) [Pubmed]
  20. Cerebrospinal fluid and behavioral changes after methyltestosterone administration: preliminary findings. Daly, R.C., Su, T.P., Schmidt, P.J., Pickar, D., Murphy, D.L., Rubinow, D.R. Arch. Gen. Psychiatry (2001) [Pubmed]
  21. A functional polymorphism in the MAOA gene promoter (MAOA-LPR) predicts central dopamine function and body mass index. Ducci, F., Newman, T.K., Funt, S., Brown, G.L., Virkkunen, M., Goldman, D. Mol. Psychiatry (2006) [Pubmed]
  22. Platelet MAO inhibition, urinary MHPG, and leukocyte beta-adrenergic receptors in depressed patients treated with phenelzine. Sharma, R.P., Janicak, P.G., Javaid, J.I., Pandey, G.N., Gierl, B., Davis, J.M. The American journal of psychiatry. (1990) [Pubmed]
  23. Central catecholamines, cognitive impairment, and affective state in elderly schizophrenics and controls. Bridge, T.P., Kleinman, J.E., Soldo, B.J., Karoum, F. Biol. Psychiatry (1987) [Pubmed]
  24. Reduced brain 5-HT and elevated NE turnover and metabolites in bipolar affective disorder. Young, L.T., Warsh, J.J., Kish, S.J., Shannak, K., Hornykeiwicz, O. Biol. Psychiatry (1994) [Pubmed]
  25. Noradrenergic function in generalized anxiety disorder, major depressive disorder, and healthy subjects. Sevy, S., Papadimitriou, G.N., Surmont, D.W., Goldman, S., Mendlewicz, J. Biol. Psychiatry (1989) [Pubmed]
  26. Rat brain and plasma norepinephrine glycol metabolites determined by gas chromatography-mass fragmentography. Warsh, J.J., Godse, D.D., Cheung, S.W., Li, P.P. J. Neurochem. (1981) [Pubmed]
  27. Monoamine neurotransmitter interactions in drug-free and neuroleptic-treated schizophrenics. Hsiao, J.K., Colison, J., Bartko, J.J., Doran, A.R., Konicki, P.E., Potter, W.Z., Pickar, D. Arch. Gen. Psychiatry (1993) [Pubmed]
  28. Abnormal regulation of noradrenergic function in panic disorders. Effects of clonidine in healthy subjects and patients with agoraphobia and panic disorder. Charney, D.S., Heninger, G.R. Arch. Gen. Psychiatry (1986) [Pubmed]
  29. Lithium carbonate treatment of mania. Cerebrospinal fluid and urinary monoamine metabolites and treatment outcome. Swann, A.C., Koslow, S.H., Katz, M.M., Maas, J.W., Javaid, J., Secunda, S.K., Robins, E. Arch. Gen. Psychiatry (1987) [Pubmed]
  30. alpha 2-Adrenergic receptor sensitivity in depression. The plasma MHPG, behavioral, and cardiovascular responses to yohimbine. Heninger, G.R., Charney, D.S., Price, L.H. Arch. Gen. Psychiatry (1988) [Pubmed]
  31. Simultaneous inhibition of catechol-O-methyltransferase and monoamine oxidase A: effects on hemodynamics and catecholamine metabolism in healthy volunteers. Illi, A., Sundberg, S., Ojala-Karlsson, P., Scheinin, M., Gordin, A. Clin. Pharmacol. Ther. (1996) [Pubmed]
  32. Dopamine-related genes and their relationships to monoamine metabolites in CSF. Jönsson, E., Sedvall, G., Brené, S., Gustavsson, J.P., Geijer, T., Terenius, L., Crocq, M.A., Lannfelt, L., Tylec, A., Sokoloff, P., Schwartz, J.C., Wiesel, F.A. Biol. Psychiatry (1996) [Pubmed]
  33. Biochemical markers and genetic research of ADHD. Paclt, I., Koudelová, J., Krepelová, A., Uhlíková, P., Gazdíková, M., Bauer, P. Neuro Endocrinol. Lett. (2005) [Pubmed]
  34. CSF and endocrine studies of premenstrual syndrome. Parry, B.L., Gerner, R.H., Wilkins, J.N., Halaris, A.E., Carlson, H.E., Hershman, J.M., Linnoila, M., Merrill, J., Gold, P.W., Gracely, R. Neuropsychopharmacology (1991) [Pubmed]
  35. Pressor response to tyramine after single 24-hour application of a selegiline transdermal system in healthy males. Barrett, J.S., Hochadel, T.J., Morales, R.J., Rohatagi, S., DeWitt, K.E., Watson, S.K., Darnow, J., Azzaro, A.J., DiSanto, A.R. Journal of clinical pharmacology. (1997) [Pubmed]
  36. Catecholamine metabolism in anorexia nervosa. Halmi, K.A., Dekirmenjian, H., Davis, J.M., Casper, R., Goldberg, S. Arch. Gen. Psychiatry (1978) [Pubmed]
  37. Primary affective disorder, clinical state change, and MHPG excretion: a longitudinal study. Pickar, D., Sweeney, D.R., Maas, J.W., Heninger, G.R. Arch. Gen. Psychiatry (1978) [Pubmed]
  38. Urinary MHPG levels and tricyclic antidepressant drug selection. A preliminary communication on improved drug selection in clinical practice. Cobbin, D.M., Requin-Blow, B., Williams, L.R., Williams, W.O. Arch. Gen. Psychiatry (1979) [Pubmed]
  39. Bioactive 6-nitronorepinephrine identified in mammalian brain. Shintani, F., Kinoshita, T., Kanba, S., Ishikawa, T., Suzuki, E., Sasakawa, N., Kato, R., Asai, M., Nakaki, T. J. Biol. Chem. (1996) [Pubmed]
WikiGenes - Universities